Abstract
Growth failure represents a significant comorbidity in pediatric systemic lupus erythematosus (cSLE), impacting physical development, psychosocial well-being, and long-term health outcomes. While the association of growth failure with the 3D-MCI in cSLE has been highlighted, this review provides a comprehensive exploration of the multifaceted etiology, diagnostic approaches, and management strategies for growth failure in this population. This report delves into the complex interplay of factors contributing to growth impairment, including disease activity, chronic inflammation, medication-related effects (particularly corticosteroids), nutritional deficiencies, hormonal disturbances, and genetic predispositions. It critically evaluates current diagnostic modalities for assessing growth and nutritional status, encompassing auxological measurements, body composition analysis, bone age assessment, and biochemical markers. Furthermore, it examines evidence-based intervention strategies aimed at optimizing growth, such as nutritional supplementation, dietary modifications, pharmacologic interventions (including growth hormone therapy and bone-sparing agents), and strategies for mitigating the adverse effects of corticosteroids. This review highlights the importance of early identification and proactive management of growth failure in cSLE to improve long-term outcomes and overall quality of life for affected children and adolescents.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
1. Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation and diverse organ involvement. Pediatric-onset SLE (cSLE) presents unique challenges compared to adult SLE, including a more aggressive disease course, higher rates of organ damage, and significant long-term morbidity. Growth failure, defined as a deviation from expected growth velocity and attainment of adult height, is a frequently observed complication in cSLE, profoundly impacting physical development, psychological well-being, and future health outcomes. Growth failure is a common comorbidity in children with chronic inflammatory diseases [1].
While the correlation between growth failure and specific disease activity measures, such as the 3D-MCI, emphasizes the clinical relevance of this complication, a comprehensive understanding of the underlying mechanisms, assessment strategies, and therapeutic interventions is crucial for effective management. This review aims to provide an in-depth analysis of the factors contributing to growth failure in cSLE, the diagnostic methods employed to assess growth and nutritional status, and the intervention strategies designed to optimize growth potential and mitigate the long-term consequences of growth impairment in affected children and adolescents.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
2. Etiology of Growth Failure in cSLE
Growth failure in cSLE is a multifactorial phenomenon arising from the complex interaction of disease-related factors, medication effects, nutritional deficiencies, and hormonal imbalances. Understanding these contributing elements is essential for developing targeted and effective intervention strategies.
2.1 Disease Activity and Chronic Inflammation
Chronic inflammation, a hallmark of cSLE, plays a central role in growth impairment. Pro-inflammatory cytokines, such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 (IL-1), are elevated in cSLE and directly interfere with growth hormone (GH) signaling and insulin-like growth factor-1 (IGF-1) production [2]. These cytokines can impair chondrocyte proliferation in the growth plate, leading to reduced bone growth. Moreover, chronic inflammation increases energy expenditure and contributes to anorexia and reduced nutrient intake, further exacerbating growth failure.
High disease activity, characterized by active lupus flares and persistent inflammation, is strongly associated with growth deceleration. Controlling disease activity through immunosuppressive therapy is crucial for mitigating the inflammatory burden and promoting growth.
2.2 Corticosteroid Therapy
Corticosteroids, such as prednisone and methylprednisolone, are frequently used as first-line agents for managing cSLE due to their potent anti-inflammatory and immunosuppressive effects. However, chronic corticosteroid use is a well-established cause of growth failure in children [3]. Corticosteroids directly suppress GH secretion, impair GH receptor sensitivity, and inhibit IGF-1 production. They also antagonize the anabolic effects of GH and IGF-1 on bone and cartilage. Furthermore, corticosteroids can induce muscle wasting, increase protein catabolism, and disrupt calcium and vitamin D metabolism, further contributing to growth impairment.
The impact of corticosteroids on growth is dose-dependent and duration-dependent. Minimizing the cumulative corticosteroid dose and utilizing alternate-day dosing regimens can help mitigate the growth-suppressing effects of these medications. Steroid-sparing agents, such as methotrexate, mycophenolate mofetil, and biologics, are increasingly used to reduce the reliance on corticosteroids and improve growth outcomes.
2.3 Nutritional Deficiencies
Nutritional deficiencies are common in cSLE due to a combination of factors, including anorexia, decreased food intake, gastrointestinal complications, and increased nutrient requirements related to inflammation. Deficiencies in essential nutrients such as protein, calories, calcium, vitamin D, and zinc can impair growth and bone development [4].
Protein-energy malnutrition is a significant concern, as it directly impacts GH secretion and IGF-1 production. Calcium and vitamin D deficiencies compromise bone mineralization and increase the risk of osteopenia and osteoporosis, further hindering growth. Zinc is essential for GH synthesis and action, and its deficiency can exacerbate growth failure.
Nutritional assessment and intervention are critical for addressing these deficiencies. Dietary counseling, nutritional supplementation, and, in some cases, enteral or parenteral nutrition may be necessary to optimize nutritional status and support growth.
2.4 Hormonal Imbalances
Hormonal imbalances can also contribute to growth failure in cSLE. Chronic inflammation and corticosteroid therapy can disrupt the hypothalamic-pituitary-gonadal (HPG) axis, leading to delayed puberty or precocious puberty. Delayed puberty can prolong the period of linear growth but may ultimately result in reduced final adult height. Precocious puberty can lead to accelerated growth initially, but premature epiphyseal fusion results in shortened adult stature. Conditions such as primary ovarian insufficiency can also present due to chronic inflammatory conditions. Furthermore, cSLE and its treatments can affect the thyroid axis, potentially causing hypothyroidism which is linked to growth deceleration [5].
2.5 Genetic Predisposition
Genetic factors may also play a role in determining growth potential in children with cSLE. Variations in genes involved in GH signaling, IGF-1 production, and bone metabolism may influence individual susceptibility to growth failure. While specific genes have not been definitively linked to growth failure in cSLE, further research is warranted to explore the role of genetic factors in modulating growth outcomes.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
3. Diagnostic Methods for Assessing Growth and Nutritional Status
A comprehensive assessment of growth and nutritional status is essential for early identification and management of growth failure in cSLE. This assessment should include auxological measurements, body composition analysis, bone age assessment, and biochemical markers.
3.1 Auxological Measurements
Auxological measurements, including height, weight, and head circumference, are fundamental in assessing growth. Height should be measured accurately using a stadiometer and plotted on age- and sex-specific growth charts. Height velocity, the rate of change in height over time, is a more sensitive indicator of growth disturbances than a single height measurement. A declining height velocity should prompt further investigation.
Weight-for-height or body mass index (BMI) is used to assess nutritional status. A low weight-for-height or BMI may indicate malnutrition or undernutrition, while a high BMI may suggest obesity, which can also impact growth and overall health.
3.2 Body Composition Analysis
Body composition analysis provides a more detailed assessment of nutritional status by quantifying fat mass, lean mass, and bone mineral density. Dual-energy X-ray absorptiometry (DEXA) is the gold standard for measuring bone mineral density and assessing body composition. DEXA can identify osteopenia and osteoporosis, which are common complications of cSLE and corticosteroid therapy. Bioelectrical impedance analysis (BIA) is a non-invasive technique that can estimate body composition by measuring the resistance to an electrical current passed through the body.
3.3 Bone Age Assessment
Bone age assessment, typically performed using a hand and wrist radiograph, provides an estimate of skeletal maturity. Bone age can be advanced or delayed relative to chronological age in children with cSLE. Advanced bone age may indicate precocious puberty or accelerated skeletal maturation, while delayed bone age may suggest growth hormone deficiency or chronic illness. The difference between bone age and chronological age can provide valuable information about growth potential and predict final adult height.
3.4 Biochemical Markers
Biochemical markers can provide insights into hormonal status, nutritional deficiencies, and bone metabolism. These markers include:
- Growth hormone (GH) and insulin-like growth factor-1 (IGF-1): Serum GH levels are pulsatile and difficult to interpret. IGF-1, a GH-dependent hormone, provides a more stable and reliable measure of GH activity. Low IGF-1 levels may suggest GH deficiency or resistance.
- Thyroid hormones: Thyroid-stimulating hormone (TSH) and free thyroxine (FT4) levels should be measured to assess thyroid function. Hypothyroidism can impair growth and should be treated promptly.
- Vitamin D and calcium: Serum 25-hydroxyvitamin D and calcium levels should be measured to assess vitamin D status and calcium metabolism. Deficiencies should be corrected with supplementation.
- Markers of bone turnover: Bone-specific alkaline phosphatase (BSAP) and C-terminal telopeptide of type I collagen (CTX) are markers of bone formation and resorption, respectively. These markers can provide information about bone turnover and response to treatment.
- Inflammatory markers: Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are markers of systemic inflammation. Elevated levels indicate active inflammation and may contribute to growth failure.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
4. Intervention Strategies to Optimize Growth
A multidisciplinary approach is essential for managing growth failure in cSLE. This approach should include optimizing disease control, minimizing corticosteroid exposure, addressing nutritional deficiencies, and considering pharmacologic interventions.
4.1 Optimizing Disease Control
Effective disease control is paramount for mitigating inflammation and promoting growth. Immunosuppressive therapy, including conventional disease-modifying antirheumatic drugs (DMARDs) and biologics, should be used to suppress disease activity and reduce the need for corticosteroids. Regular monitoring of disease activity and prompt treatment of flares are crucial for preventing growth impairment.
4.2 Minimizing Corticosteroid Exposure
Corticosteroid-sparing strategies should be employed whenever possible to reduce the growth-suppressing effects of these medications. These strategies include:
- Using the lowest effective dose of corticosteroids: Corticosteroid doses should be tapered as quickly as possible while maintaining disease control.
- Alternate-day dosing: Alternate-day corticosteroid regimens may be less growth-suppressing than daily dosing.
- Topical or local corticosteroids: Topical or local corticosteroids should be used whenever appropriate to minimize systemic exposure.
- Steroid-sparing agents: Methotrexate, mycophenolate mofetil, azathioprine, and biologics can be used to reduce the reliance on corticosteroids.
4.3 Addressing Nutritional Deficiencies
Nutritional assessment and intervention are essential for addressing nutritional deficiencies and optimizing growth. This includes:
- Dietary counseling: A registered dietitian should provide dietary counseling to ensure adequate intake of calories, protein, calcium, vitamin D, and other essential nutrients.
- Nutritional supplementation: Oral nutritional supplements may be necessary to meet nutrient requirements, particularly in children with anorexia or poor appetite. Vitamin D and calcium supplementation are often recommended.
- Enteral or parenteral nutrition: In severe cases of malnutrition or gastrointestinal dysfunction, enteral or parenteral nutrition may be necessary to provide adequate nutrition.
4.4 Pharmacologic Interventions
Pharmacologic interventions may be considered in selected cases of growth failure in cSLE. These interventions include:
- Growth hormone therapy: Growth hormone (GH) therapy can be effective in improving growth velocity and final adult height in children with GH deficiency or those who are short for their age despite adequate disease control and nutritional support [6]. However, GH therapy is not without risks, and careful monitoring is required. Concerns exist regarding the potential for GH to exacerbate autoimmune activity in SLE, so use is generally restricted to patients with well-controlled disease and under close supervision.
- Bisphosphonates: Bisphosphonates, such as alendronate and risedronate, are medications that inhibit bone resorption and increase bone mineral density. They may be considered in children with cSLE who have osteoporosis or are at high risk for fractures, particularly those on long-term corticosteroid therapy. Side effects need to be carefully considered.
- Vitamin D analogs: Calcitriol is an activated form of vitamin D that can improve calcium absorption and bone mineralization. It may be considered in children with cSLE who have vitamin D deficiency or are at high risk for osteoporosis.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
5. Long-Term Impact of Growth Failure on Overall Health and Quality of Life
Growth failure in cSLE can have significant long-term consequences on overall health and quality of life. These include:
- Reduced adult height: Growth failure can result in reduced final adult height, which may impact self-esteem and social interactions.
- Osteoporosis and fractures: Chronic inflammation and corticosteroid therapy can increase the risk of osteoporosis and fractures, leading to pain, disability, and reduced quality of life.
- Cardiovascular disease: Studies have linked growth failure to an increased risk of cardiovascular disease in adulthood.
- Psychosocial problems: Growth failure can contribute to anxiety, depression, and social isolation.
- Impaired reproductive function: Disruption of the HPG axis can lead to delayed puberty, infertility, and other reproductive problems.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
6. Conclusion
Growth failure is a significant comorbidity in cSLE, resulting from a complex interplay of disease activity, medication effects, nutritional deficiencies, and hormonal imbalances. Early identification and proactive management are essential for optimizing growth potential and mitigating the long-term consequences of growth impairment. A multidisciplinary approach, including optimizing disease control, minimizing corticosteroid exposure, addressing nutritional deficiencies, and considering pharmacologic interventions, is crucial for improving growth outcomes and overall quality of life for children and adolescents with cSLE. Further research is needed to better understand the genetic and environmental factors that contribute to growth failure in cSLE and to develop more targeted and effective therapies.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
References
[1] Beukelman, T., et al. “Longitudinal assessment of growth and puberty in children with juvenile idiopathic arthritis.” Arthritis & Rheumatism 54.7 (2006): 2418-2426.
[2] De Benedetti, F., et al. “Interleukin 6 causes growth impairment and anaemia in transgenic mice.” The Journal of Clinical Investigation 99.4 (1997): 643-650.
[3] Allen, D. B. “Glucocorticoid-induced osteoporosis and growth suppression: implications for pediatric patients.” Advances in pediatrics 43 (1996): 187-216.
[4] Shaw, V., and S. Lawson. Clinical Paediatric Dietetics. Blackwell Publishing, 2007.
[5] Segni, M., et al. “Thyroid autoimmunity and rheumatic diseases in children and adolescents: a possible link.” Autoimmunity reviews 14.7 (2015): 627-631.
[6] Allen, D. B., et al. “Effects of growth hormone treatment on bone mineral density in children receiving glucocorticoids.” Journal of Pediatrics 137.4 (2000): 542-548.
Be the first to comment